MetaCap

Adagene (ADAG) vs Sionna Therapeutics (SION)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adagene (ADAG) has outperformed Sionna Therapeutics (SION) over the past year, losing 2.2% versus a loss of 93.5%. Sionna Therapeutics is the larger company by market cap ($127.8 million vs $118.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADAG-2.22%SION-93.53%
+179%+36%-106%
Nov 21, 20251 yearNov 20, 2026
ADAG+2.33%SION-88.70%
+172%+36%-101%
Feb 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADAG versus SION key metrics
MetricADAGSION
Share price$1.76$2.83
Market cap$118.17M$127.79M
1-day change-12.44%-4.88%
YTD return-6.88%-93.13%
1-year return-2.22%-93.53%
5-year return-79.75%—
EPS (TTM)$-0.37$-2.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.67M—
Revenue growth (YoY)+7332.76%—
Net income (latest FY)$-17.61M$-75.27M
Operating margin-279.48%—
Net margin-229.56%—
52-week high$4.85$54.97
52-week low$1.27$2.75
Distance from 52-week high-63.71%-94.86%
Analyst consensusnonehold
Avg. price target upside+463.07%+643.36%
Average volume348.81K1.12M
Shares outstanding67.14M45.24M
Employees12859
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ADAG has outperformed SION by 91.3 percentage points over the past year.

About Adagene

ADAG stock →

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Sionna Therapeutics

SION stock →

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees

ADAG vs SION FAQ

Which is bigger, Adagene or Sionna Therapeutics?

Sionna Therapeutics (SION) is larger, with a market capitalization of $127.79M compared with $118.17M for Adagene (ADAG).

Which stock has performed better over the past year, ADAG or SION?

ADAG returned -2.22% over the past 12 months, compared with -93.53% for SION (price return, excluding dividends). Past performance does not predict future results.

Are Adagene and Sionna Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons